Acceleron commences ACE-536 phase 2 research in beta-thalassemia Acceleron Pharma, Inc., a biopharmaceutical company developing proteins therapeutics for cancer and orphan diseases, announced the initiation of a stage 2 study of its novel today, investigational protein therapeutic, ACE-536, to take care of patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and significant problems affecting the spleen, liver and heart. Patients and healthcare companies currently have limited options for the treating beta-thalassemia. This is actually the second ongoing Phase 2 trial for ACE-536, which is being developed by Acceleron within a worldwide collaboration with Celgene Corporation .Related StoriesNew UCLA research looks at primary care medical home in reducing childrens' repeat appointments to hospitalsGlan Clwyd Medical center N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanningFirst hospital installs Ortho Vision AnalyzerThroughout Leanne Schoberl's life, Oleske visited extraordinary lengths to make her illnesses and treatments seeing that easy to tolerate seeing that possible. If Oleske required a blood sample, John Schoberl says he proved helpful extra hard to find minimal painful spot, instead of poking her a dozen or more times in hands that had become pincushions. If Leanne needed complicated transfusions, he ensured she could easily get them in the home where she would be most comfortable.